Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Adiposity and Low Total Serum Bilirubin Concentration: A Retrospective, Cross-Sectional Study.

Health science reports·2025
Same author

Management of extracervical recurrence following total parathyroidectomy and autotransplantation for renal hyperparathyroidism.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2025
Same author

Therapies and Pipeline for Hepatitis B and Hepatitis D.

Clinics in liver disease·2025
Same author

Barriers and enablers to medical students' engagement in research and clinical academic careers: a mixed-methods study.

BMJ open·2025
Same author

The Regulation of Catecholamine Biosynthesis by the Gas Transmitters Carbon Monoxide and Hydrogen Sulfide.

Current issues in molecular biology·2025
Same author

Parents' Industrial Sectors and Fields of Study: Five Decades of Evidence from an Elite Regional University in China.

Sociology·2025
Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K

Artificial Intelligence and Machine Learning Applications in Liver Disease.

Bhargav Vemulapalli1, Meghana Ghattu1, Kavya Atluri1

  • 1Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ, USA.

Clinics in Liver Disease
|October 18, 2025
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) and machine learning (ML) are revolutionizing liver disease care by integrating diverse data for earlier diagnosis and personalized management. These advancements promise improved patient outcomes across various liver conditions.

Keywords:
Artificial intelligenceCirrhosisHepatitis CLiver imagingMASLDMachine learningTransplantationWearables

More Related Videos

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.8K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.7K

Related Experiment Videos

Last Updated: Jan 14, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
06:09

Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI

Published on: July 21, 2023

1.8K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.7K

Area of Science:

  • Hepatology
  • Medical Informatics
  • Artificial Intelligence

Background:

  • Hepatology is increasingly leveraging data-driven approaches.
  • Integrating diverse patient data (clinical, lab, imaging, wearable) presents challenges and opportunities.
  • Current management strategies can benefit from enhanced predictive and diagnostic tools.

Purpose of the Study:

  • To review the transformative impact of AI and ML in hepatology.
  • To highlight applications in early diagnosis, risk prediction, and patient management.
  • To discuss the role of AI/ML across key liver diseases and future directions.

Main Methods:

  • Review of current literature on AI and ML applications in hepatology.
  • Synthesis of findings related to data integration and disease management.
  • Analysis of trends in digital health and AI interpretability.

Main Results:

  • AI and ML are enabling earlier diagnosis and risk prediction in liver diseases.
  • Personalized patient care and noninvasive monitoring are enhanced by these technologies.
  • Applications span metabolic dysfunction-associated steatotic liver disease, cirrhosis, hepatitis C, liver transplantation, and hepatocellular carcinoma.

Conclusions:

  • AI and ML are integral to the future of hepatology.
  • Continued advances in digital health and interpretability will drive wider adoption.
  • These technologies will significantly improve patient outcomes and management strategies.